Kurve Therapeutics is developing disease-modifying drugs with demonstrated clinical efficacy in cognitive aging, neurodegenerative diseases and related disorders.
Much of this efficacy can be traced to inhibition of two key enzymes that have for over a decade been an elusive target for Alzheimer’s drugs: Glycogen synthase kinase-3 beta (GSK-3 beta) and elongation factor 2 kinase (EF2K).
Our technology platform enhances efficacy and avoids systemic side-effects by delivering drugs directly to the brain. This is done with precisely-controlled, turbulent flow from an intranasal device.
The largest body of clinical evidence for our technology platform is in Alzheimer’s disease (a severe form of cognitive aging), where we have significant, placebo-controlled results in five Phase II trials.
We also have favorable, placebo-controlled results for cognitive aging in diabetes patients (≥ 50 years old) and age-matched controls.
Our Parkinson’s pilot study, though small, produced significant, placebo-controlled results in cognition and favorable improvements in motor function.
Much of our work is driven by recent and ongoing collaborations with academic medical centers, government institutions and industry.
Additionally, some individual patients, using our drugs under the guidance of their physicians (i.e., under compassionate use outside clinical trials), have generously shared their experience.
We are led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals and device technology.